{"id":"NCT01963143","sponsor":"Bio Products Laboratory","briefTitle":"Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases","officialTitle":"A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2016-01","completion":"2016-05","firstPosted":"2013-10-16","resultsPosted":"2017-03-29","lastUpdate":"2017-03-29"},"enrollment":48,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Deficiency Disorders","Common Variable Immunodeficiency","X-linked Agammaglobulinaemia","Hyper-IgM Syndrome"],"interventions":[{"type":"BIOLOGICAL","name":"Gammaplex (5%)","otherNames":[]},{"type":"BIOLOGICAL","name":"Gammaplex 10","otherNames":[]}],"arms":[{"label":"Treatment Sequence 1 - Adults","type":"EXPERIMENTAL"},{"label":"Treatment Sequence 2 - Adults","type":"EXPERIMENTAL"},{"label":"Pediatrics","type":"EXPERIMENTAL"}],"summary":"The primary objective is to demonstrate the bioequivalence of Gammaplex® 10 intravenous immunoglobulin (IGIV) and Gammaplex® 5% IGIV with respect to area under the curve within a 28-day dosing interval (AUC0-28) in a cohort of adult subjects.\n\nThe secondary objectives are to demonstrate the bioequivalence of Gammaplex® 10 IGIV and Gammaplex® 5% IGIV with respect to area under the curve within a 21-day dosing interval (AUC0-21) in adult subjects; to assess the pharmacokinetics of Gammaplex 10 IGIV and Gammaplex 5% IGIV including Immunoglobulin G (IgG) trough levels and to investigate the safety and tolerability of Gammaplex 10 IGIV and Gammaplex 5% IGIV in adults subjects; to assess the pharmacokinetics of Gammaplex 10 IGIV including IgG trough levels and to investigate the safety and tolerability of Gammaplex 10 IGIV in pediatric subjects.","primaryOutcome":{"measure":"Primary Bioequivalence Analysis - Area Under the Curve Within a 28-day Dosing Interval (AUC0-28) in Adult Subjects","timeFrame":"After a minimum 5 infusions on each product, at pre-infusion, 10 minutes before end of infusion, 1, 3, 6, 24, 48 hours, 4, 7, 14, 21 and 28 days post-infusion","effectByArm":[{"arm":"Gammaplex 10%","deltaMin":1.01,"sd":null},{"arm":"Gammaplex 5%","deltaMin":1.01,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["United States","Hungary","United Kingdom"]},"refs":{"pmids":["39919133","36818468"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":33},"commonTop":["Headache","Upper respiratory tract infection","Viral upper respiratory tract infection","Acute sinusitis","Sinusitis"]}}